204 related articles for article (PubMed ID: 29649284)
1. Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma.
Nagane M; Kanai E; Shibata Y; Shimizu T; Yoshioka C; Maruo T; Yamashita T
PLoS One; 2018; 13(4):e0195151. PubMed ID: 29649284
[TBL] [Abstract][Full Text] [Related]
2. Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury.
Meyer AR; Engevik AC; Willet SG; Williams JA; Zou Y; Massion PP; Mills JC; Choi E; Goldenring JR
Cell Mol Gastroenterol Hepatol; 2019; 8(3):379-405. PubMed ID: 31071489
[TBL] [Abstract][Full Text] [Related]
3. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion.
Sleire L; Skeie BS; Netland IA; Førde HE; Dodoo E; Selheim F; Leiss L; Heggdal JI; Pedersen PH; Wang J; Enger PØ
Oncogene; 2015 Dec; 34(49):5951-9. PubMed ID: 25798841
[TBL] [Abstract][Full Text] [Related]
4. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
5. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases.
Lo M; Wang YZ; Gout PW
J Cell Physiol; 2008 Jun; 215(3):593-602. PubMed ID: 18181196
[TBL] [Abstract][Full Text] [Related]
6. The role of system Xc
Dang DK; Shin EJ; Tran HQ; Kim DJ; Jeong JH; Jang CG; Nah SY; Sato H; Nabeshima T; Yoneda Y; Kim HC
Neurochem Int; 2017 Sep; 108():254-265. PubMed ID: 28457879
[TBL] [Abstract][Full Text] [Related]
7. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
[TBL] [Abstract][Full Text] [Related]
8. Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells.
Okamoto K; Saito Y; Ueda H; Narumi K; Furugen A; Kobayashi M
Biopharm Drug Dispos; 2021 Sep; 42(8):389-392. PubMed ID: 34287957
[TBL] [Abstract][Full Text] [Related]
9. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death.
Banjac A; Perisic T; Sato H; Seiler A; Bannai S; Weiss N; Kölle P; Tschoep K; Issels RD; Daniel PT; Conrad M; Bornkamm GW
Oncogene; 2008 Mar; 27(11):1618-28. PubMed ID: 17828297
[TBL] [Abstract][Full Text] [Related]
10. Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer.
Sendo K; Seino M; Ohta T; Nagase S
Oncotarget; 2022; 13():224-236. PubMed ID: 35106124
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species involved in the glutamate toxicity of C6 glioma cells via xc antiporter system.
Mawatari K; Yasui Y; Sugitani K; Takadera T; Kato S
Neuroscience; 1996 Jul; 73(1):201-8. PubMed ID: 8783242
[TBL] [Abstract][Full Text] [Related]
12. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
Guan J; Lo M; Dockery P; Mahon S; Karp CM; Buckley AR; Lam S; Gout PW; Wang YZ
Cancer Chemother Pharmacol; 2009 Aug; 64(3):463-72. PubMed ID: 19104813
[TBL] [Abstract][Full Text] [Related]
13. Burn injury induces the expression of cystine/glutamate transporter (x(c)(-)) in mouse T cells.
D'Elia M; Patenaude J; Dupras C; Bernier J
Immunol Lett; 2009 Aug; 125(2):137-44. PubMed ID: 19576933
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines.
Pham AN; Blower PE; Alvarado O; Ravula R; Gout PW; Huang Y
J Pharmacol Exp Ther; 2010 Mar; 332(3):949-58. PubMed ID: 20007406
[TBL] [Abstract][Full Text] [Related]
15. The Styryl Benzoic Acid Derivative DC10 Potentiates Radiotherapy by Targeting the xCT-Glutathione Axis.
Sarowar S; Cirillo D; Játiva P; Nilsen MH; Otragane SA; Heggdal J; Selheim F; Ceña V; Bjørsvik HR; Enger PØ
Front Oncol; 2022; 12():786739. PubMed ID: 35198439
[TBL] [Abstract][Full Text] [Related]
16. Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc
Guo W; Li K; Sun B; Xu D; Tong L; Yin H; Liao Y; Song H; Wang T; Jing B; Hu M; Liu S; Kuang Y; Ling J; Li Q; Wu Y; Wang Q; Yao F; Zhou BP; Lin SH; Deng J
Cancer Res; 2021 Feb; 81(3):552-566. PubMed ID: 33229341
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of xc⁻ transporter-mediated cystine uptake by sulfasalazine analogs.
Shukla K; Thomas AG; Ferraris DV; Hin N; Sattler R; Alt J; Rojas C; Slusher BS; Tsukamoto T
Bioorg Med Chem Lett; 2011 Oct; 21(20):6184-7. PubMed ID: 21889337
[TBL] [Abstract][Full Text] [Related]
18. Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation.
Shih AY; Erb H; Sun X; Toda S; Kalivas PW; Murphy TH
J Neurosci; 2006 Oct; 26(41):10514-23. PubMed ID: 17035536
[TBL] [Abstract][Full Text] [Related]
19. Tumor growth inhibitory effect of juglone and its radiation sensitizing potential: in vivo and in vitro studies.
Aithal KB; Kumar S; Rao BN; Udupa N; Rao SB
Integr Cancer Ther; 2012 Mar; 11(1):68-80. PubMed ID: 21498474
[TBL] [Abstract][Full Text] [Related]
20. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
